Wellington Management Group LLP Increases Position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Wellington Management Group LLP boosted its holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 54.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 241,299 shares of the biopharmaceutical company’s stock after purchasing an additional 85,455 shares during the period. Wellington Management Group LLP owned about 0.44% of Marinus Pharmaceuticals worth $2,623,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Franklin Resources Inc. raised its position in shares of Marinus Pharmaceuticals by 1.3% in the 4th quarter. Franklin Resources Inc. now owns 3,833,955 shares of the biopharmaceutical company’s stock valued at $41,675,000 after purchasing an additional 49,589 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Marinus Pharmaceuticals by 6.3% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company’s stock worth $23,381,000 after acquiring an additional 173,226 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Marinus Pharmaceuticals by 1.2% in the third quarter. Vanguard Group Inc. now owns 2,577,475 shares of the biopharmaceutical company’s stock worth $20,749,000 after acquiring an additional 31,233 shares during the last quarter. abrdn plc acquired a new position in Marinus Pharmaceuticals in the fourth quarter valued at approximately $6,006,000. Finally, Superstring Capital Management LP acquired a new position in Marinus Pharmaceuticals during the 4th quarter valued at approximately $5,027,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS stock opened at $1.17 on Monday. The company has a market capitalization of $64.27 million, a price-to-earnings ratio of -0.44 and a beta of 1.11. Marinus Pharmaceuticals, Inc. has a 1-year low of $1.10 and a 1-year high of $11.26. The company has a current ratio of 3.07, a quick ratio of 2.93 and a debt-to-equity ratio of 5.68. The stock’s fifty day simple moving average is $1.41 and its 200-day simple moving average is $6.42.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.68). Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative return on equity of 518.13%. The company had revenue of $7.68 million during the quarter, compared to analyst estimates of $8.61 million. On average, sell-side analysts predict that Marinus Pharmaceuticals, Inc. will post -1.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

MRNS has been the subject of a number of recent research reports. Truist Financial restated a “buy” rating and set a $10.00 price objective on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Robert W. Baird reiterated a “neutral” rating on shares of Marinus Pharmaceuticals in a research report on Tuesday, April 16th. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Royal Bank of Canada reissued a “sector perform” rating and set a $3.00 target price (down previously from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday, April 15th. Finally, StockNews.com cut shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $13.79.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.